CO2019012888A2 - Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas - Google Patents

Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas

Info

Publication number
CO2019012888A2
CO2019012888A2 CONC2019/0012888A CO2019012888A CO2019012888A2 CO 2019012888 A2 CO2019012888 A2 CO 2019012888A2 CO 2019012888 A CO2019012888 A CO 2019012888A CO 2019012888 A2 CO2019012888 A2 CO 2019012888A2
Authority
CO
Colombia
Prior art keywords
antimitoskines
stem cells
cancer stem
specific inhibitors
mitochondrial biogenesis
Prior art date
Application number
CONC2019/0012888A
Other languages
English (en)
Inventor
Michael P Lisanti
Federica Sotgia
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of CO2019012888A2 publication Critical patent/CO2019012888A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70585—CD44

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Los antibióticos que tienen propiedades anti-mitocondriales intrínsecas se pueden modificar químicamente para dirigir los antibióticos a las mitocondrias, y las "antimitoscinas" resultantes pueden tener propiedades anticancerosas mejoradas, entre otras propiedades ventajosas. También se describen métodos para identificar antimitoscinas, métodos para usar antimitoscinas para fijar como objetivo células madre cancerosas y composiciones farmacéuticas para tratar el cáncer que contienen una o más antimitoscinas como el ingrediente activo. También se dan a conocer compuestos específicos de antimitoscinas y grupos de antimitoscinas.
CONC2019/0012888A 2017-05-19 2019-11-18 Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas CO2019012888A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508702P 2017-05-19 2017-05-19
PCT/US2018/033466 WO2018213751A1 (en) 2017-05-19 2018-05-18 Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells

Publications (1)

Publication Number Publication Date
CO2019012888A2 true CO2019012888A2 (es) 2020-05-15

Family

ID=64274780

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0012888A CO2019012888A2 (es) 2017-05-19 2019-11-18 Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas

Country Status (20)

Country Link
US (2) US11160821B2 (es)
EP (1) EP3624840A4 (es)
JP (1) JP6938682B2 (es)
KR (1) KR20200010343A (es)
CN (1) CN111315400A (es)
AU (1) AU2018270129B2 (es)
BR (1) BR112019024264A2 (es)
CA (1) CA3063717C (es)
CL (1) CL2019003283A1 (es)
CO (1) CO2019012888A2 (es)
CR (1) CR20190524A (es)
CU (1) CU20190092A7 (es)
DO (1) DOP2019000294A (es)
EC (1) ECSP19082194A (es)
IL (1) IL270598B (es)
MX (1) MX2019013735A (es)
PE (1) PE20200605A1 (es)
RU (1) RU2019142102A (es)
WO (1) WO2018213751A1 (es)
ZA (3) ZA201907654B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
WO2018195446A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
CR20190524A (es) 2017-05-19 2020-01-10 Lunella Biotech Inc Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas
CA3063450A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
MX2019014806A (es) 2017-06-26 2020-02-10 Lunella Biotech Inc Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas.
WO2019075226A1 (en) 2017-10-11 2019-04-18 Lunella Biotech, Inc. ANTI-MITOCHONDRIAL INHIBITORS FOR ONCOGENIC RAS AND MYC
CA3083487A1 (en) * 2017-12-01 2019-06-06 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
PE20211006A1 (es) 2018-10-02 2021-06-01 Lunella Biotech Inc Derivados de azitromicina y roxitromicina como farmacos senoliticos
CN113573715A (zh) * 2018-12-17 2021-10-29 卢内拉生物技术有限公司 用于靶向线粒体和杀死癌症干细胞的三联疗法
AU2019402099A1 (en) * 2018-12-17 2021-07-08 Lunella Biotech, Inc. Triple combination therapies for anti-aging
US11672810B2 (en) 2019-05-24 2023-06-13 Lunella Biotech, Inc. Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer
KR20220025849A (ko) * 2019-06-26 2022-03-03 루넬라 바이오테크 인코포레이티드 미토콘드리아의 표적화 및 암 줄기 세포의 근절을 위한 카르보시아닌 화합물
WO2021081500A1 (en) 2019-10-24 2021-04-29 The Medical College Of Wisconsin, Inc. Mitochondria-targeted atovaquone: a more potent and more effective antitumor, antimicrobial, and antimalarial drug
CN115551827A (zh) * 2020-05-13 2022-12-30 卢内拉生物技术有限公司 靶向癌症干细胞和防止转移的9-氨基-多西环素肉豆蔻酰衍生物
CA3198350A1 (en) * 2020-10-22 2022-04-28 Lunella Biotech, Inc. Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasis

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2862921A (en) * 1953-08-13 1958-12-02 Upjohn Co Erythromycin esters
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DK149776C (da) * 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
EP0310361A3 (en) 1987-09-30 1989-05-24 Beckman Instruments, Inc. Tridentate conjugate and method of use thereof
SI9011409A (en) 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
EP0656422B1 (en) 1993-11-05 2000-04-26 Amersham Pharmacia Biotech UK Limited Chloramphenicol acetyl transferase (CAT) assay
WO1995015770A1 (en) 1993-12-09 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US5441939A (en) 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
EP0758549A4 (en) 1994-04-26 1997-07-02 Nobuhiro Narita MEDICAL COMPOSITION AS A MEDICINE FOR NON-SMALL CELL CANCER
JPH11504916A (ja) 1995-05-03 1999-05-11 ファイザー・インコーポレーテッド 新規テトラサイクリン誘導体
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
NZ505352A (en) 1997-11-25 2002-12-20 Univ Otago Mitochondrially targeted antioxidants
ATE275151T1 (de) 1998-03-03 2004-09-15 Pfizer Prod Inc 3,6-ketal-makrolidantibiotika
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP2005538035A (ja) * 2001-12-11 2005-12-15 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ グアニジニウム輸送試薬および結合体
US7485298B2 (en) 2002-05-23 2009-02-03 Michael Powell Diagnosis and treatment of human dormancy-related sequellae
RU2223103C1 (ru) 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая антибактериальным действием
EP2529758A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
WO2005062851A2 (en) 2003-12-22 2005-07-14 Pappolla Miguel A Indole-3-propionamide and derivatives thereof
EP1555021A1 (en) 2004-01-16 2005-07-20 National Health Research Institutes Combinations of a mevalonate pathway inhibitor and a PPAR-gamma agonist for treating cancer
JP2007523912A (ja) 2004-02-26 2007-08-23 アドバンスト アキュラー システムズ リミテッド 眼病変治療用へパリン
US20060083727A1 (en) 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
EP1836212B1 (en) 2005-01-14 2011-09-07 Glaxo Group Limited Macrolide compounds containing biotin and photo-affinity group for macrolide target identification
CN1706391A (zh) 2005-05-09 2005-12-14 史同瑞 土霉素混悬乳剂
NZ587586A (en) 2005-07-18 2012-04-27 Bipar Sciences Inc Treatment of cancer
CN1837229A (zh) 2005-08-05 2006-09-27 济南思创生物技术有限公司 克拉霉素衍生物及其制备方法和药物应用
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
CN1837225A (zh) 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
MX2008014953A (es) 2006-05-26 2009-03-05 Bayer Healthcare Llc Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer.
US20090311249A1 (en) 2006-06-02 2009-12-17 Luca Gianni Capecitabine Combination Therapy
EP2526970A1 (en) * 2006-09-07 2012-11-28 Stemline Therapeutics, Inc. Monitoring cancer stem cells
AU2007314366A1 (en) 2006-10-30 2008-05-08 Southern Research Institute Targeting NBS1-ATM interaction to sensitize cancer cells to radiotherapy and chemotherapy
SI2117520T1 (sl) 2006-12-14 2019-01-31 Abraxis Bioscience, Llc Zdravljenje raka dojk glede na status hormonskih receptorjev z nano delci, ki zajemajo taksan
US8075902B2 (en) 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
DE102007025423A1 (de) 2007-05-30 2008-12-04 Friedrich-Schiller-Universität Jena Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung
WO2008150845A1 (en) 2007-05-31 2008-12-11 Vanderbilt University Screening for wnt pathway modulators and pyrvinium for the treatment of cance
WO2009015214A2 (en) 2007-07-24 2009-01-29 Wayne State University Nanoparticles for imaging and treating chlamydial infection
WO2009036092A2 (en) 2007-09-10 2009-03-19 University Of Massachusetts Mitochondria-targeted anti-tumor agents
WO2009038656A1 (en) 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
WO2009045443A2 (en) 2007-10-02 2009-04-09 The University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
WO2010121177A2 (en) 2009-04-17 2010-10-21 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
GB0912584D0 (en) 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
CN102596192A (zh) 2009-08-25 2012-07-18 哈佛大学校长及研究员协会 二甲双胍在癌症治疗和预防中的用途
DK2338476T3 (da) * 2009-12-02 2012-09-17 Bettina Heil Suppositorium til rektal, vaginal eller urethral indgivelse indeholdende et probiotikum, et antibiotikum og en umættet ikke-forestret fedtsyre
PT2506840T (pt) 2009-12-04 2021-04-27 Oncoc4 Inc Utilizações de inibidores de fatores induzíveis de hipoxia
CA2790240A1 (en) 2010-03-10 2011-09-15 University Health Network Use of tigecycline for treatment of cancer
CN101810570B (zh) * 2010-04-16 2012-06-20 成都师创生物医药科技有限公司 蒽环类抗肿瘤抗生素脂肪酸复合物脂质纳米粒制剂及其制备方法
US20110268722A1 (en) * 2010-04-22 2011-11-03 Siegelin Markus D Combination therapies with mitochondrial-targeted anti-tumor agents
US20120141467A1 (en) 2010-12-03 2012-06-07 Schneider Daniel J Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma
US10513539B2 (en) 2011-02-10 2019-12-24 Ruprecht-Karls-Universitat Heidelberg Hydrophobic modified peptides and their use for liver specific targeting
US9907812B2 (en) 2011-06-22 2018-03-06 Vyome Biosciences Pvt. Ltd. Conjugate-based antifungal and antibacterial prodrugs
EP3111937B1 (en) 2011-07-08 2020-06-17 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
WO2013019975A1 (en) 2011-08-03 2013-02-07 University Of Iowa Research Foundation Compositions and methods of treating cancer
CN102911226B (zh) * 2011-08-03 2015-11-25 胡梨芳 硬脂酸红霉素类化合物物实体及其用途
US9180134B2 (en) 2011-08-18 2015-11-10 Ecole Polytechnique Federale De Lausanne (Epel) Mitochondrial ribosomal proteins as aging regulators
US9775855B2 (en) 2011-09-14 2017-10-03 Thomas J. Lewis Compositions comprising macrolide and tetracycline and their uses
EP2819993B1 (en) 2012-03-01 2020-09-02 University Of Cincinnati Ros-activated compounds as selective anti-cancer therapeutics
WO2014036037A1 (en) 2012-08-28 2014-03-06 Annam Biosciences, Llc N-boc-dendrimers and their conjugates
WO2014036654A1 (en) 2012-09-06 2014-03-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
US20140106004A1 (en) 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
US9636329B2 (en) 2012-11-06 2017-05-02 Northwestern University Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors
US9622982B2 (en) 2013-01-14 2017-04-18 Health Clinics Limited Cancer drug and uses
US9937161B2 (en) 2013-03-06 2018-04-10 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
AU2014256546B2 (en) 2013-04-24 2017-03-30 Biotechnologicky Ustav Av Cr, V.V.I. Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level
WO2015002996A1 (en) 2013-07-01 2015-01-08 University Of Georgia Research Foundation, Inc. Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
CN103536530A (zh) 2013-10-30 2014-01-29 王玉万 盐酸多西环素长效注射剂及制备方法
US20150231069A1 (en) 2014-02-20 2015-08-20 Pankaj Modi Oral formulations of chemotherapeutic agents
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US20170224730A1 (en) 2014-06-10 2017-08-10 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
US10413558B2 (en) 2014-10-17 2019-09-17 Targeted Therapies Research And Consulting Center Sprl Multi-ingredient pharmaceutical composition for use in cancer therapy
CN104352566A (zh) 2014-10-21 2015-02-18 河南牧翔动物药业有限公司 一种水包油型复方金霉素纳米乳
JP6439931B2 (ja) 2015-02-26 2018-12-19 大日本印刷株式会社 吸着搬送装置および吸着搬送方法
MX2018004309A (es) 2015-10-06 2018-05-22 Redhill Biopharma Ltd Terapias combinadas para tratar el cancer.
CN105884633B (zh) 2016-05-07 2017-12-26 浙江大学 一种四环素硬脂酸嫁接物及其制备和应用
US11725041B2 (en) 2016-08-11 2023-08-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds
CN106511317A (zh) 2016-12-13 2017-03-22 浙江中同科技有限公司 一种掩味克拉霉素颗粒的制备方法
WO2018136598A1 (en) 2017-01-18 2018-07-26 Evelo Biosciences, Inc. Methods of treating cancer
WO2018136617A2 (en) 2017-01-18 2018-07-26 Evelo Biosciences, Inc. Methods of treating cancer
WO2018195446A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
WO2018202910A1 (en) 2017-05-05 2018-11-08 Fondazione Istituto Italiano Di Tecnologia Combination of antibiotic and bcl-2 inhibitor and uses thereof
CA3063450A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
CR20190524A (es) 2017-05-19 2020-01-10 Lunella Biotech Inc Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas
WO2018218242A1 (en) 2017-05-26 2018-11-29 Epicentrx, Inc. Methods and compositions for combination therapy
CN111971040B (zh) 2017-11-24 2022-05-27 卢内拉生物技术有限公司 用于根除癌症干细胞的三苯基鏻衍生物化合物
EP3728300A4 (en) 2017-12-20 2021-08-11 Lunella Biotech, Inc. TARGETING MITOCHONDRIAL FISSION VIA MDIVI-1 DERIVATIVES

Also Published As

Publication number Publication date
NZ760422A (en) 2023-11-24
KR20200010343A (ko) 2020-01-30
CL2019003283A1 (es) 2020-05-04
MX2019013735A (es) 2020-01-15
AU2018270129B2 (en) 2021-01-07
US11160821B2 (en) 2021-11-02
JP2020527127A (ja) 2020-09-03
CR20190524A (es) 2020-01-10
RU2019142102A (ru) 2021-06-21
WO2018213751A1 (en) 2018-11-22
ZA202202712B (en) 2023-11-29
CA3063717A1 (en) 2018-11-22
AU2018270129A1 (en) 2020-01-16
IL270598B (en) 2022-04-01
JP6938682B2 (ja) 2021-09-22
RU2019142102A3 (es) 2021-06-21
US11865130B2 (en) 2024-01-09
DOP2019000294A (es) 2020-02-16
US20220072020A1 (en) 2022-03-10
US20200179424A1 (en) 2020-06-11
ZA201907654B (en) 2022-07-27
ECSP19082194A (es) 2019-11-30
ZA202102509B (en) 2023-03-29
EP3624840A1 (en) 2020-03-25
CA3063717C (en) 2021-08-24
CU20190092A7 (es) 2020-10-20
EP3624840A4 (en) 2021-03-10
CN111315400A (zh) 2020-06-19
BR112019024264A2 (pt) 2020-06-02
PE20200605A1 (es) 2020-03-10

Similar Documents

Publication Publication Date Title
DOP2019000294A (es) Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
CL2019003542A1 (es) Métodos de tratamiento para la fibrosis quística.
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2018001996A1 (es) Composiciones y métodos para modular la expresión del factor b del complemento (divisional de solicitud 2764-16)
CL2023002383A1 (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
GT201400043A (es) Imidazopiridazinas sustituidas con amino
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CO2019002246A2 (es) Compuesto heterocíclico nitrogenado bicíclico
NI202000031A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
PE20200295A1 (es) Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas
ECSP15003613A (es) Formulación transdérmica que contiene inhibidores de cox
BR112017004304A2 (pt) composições de pteroestilbeno tópicas para uso em tratamento de perda de função de barreira na pele induzidas por uv
CO2020006648A2 (es) Derivados de imidazopiridina y su uso como medicamento
BR112015014367A2 (pt) formulações inibidoras de lfa-1
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
AR093822A1 (es) Procedimientos para combatir plantas dañinas resistentes
CO2021004612A2 (es) Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento